Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide

29 March 2022

Next webinar organised by ERN-RND will be on :

‘Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide’​ by Annemieke Aartsma-Rus

29 March 2022, 3-4pm CEST

The speaker is Professor of Translational Genetics at the Department of Human Genetics at the Leiden University Medical Center, the Netherlands. She is also Co-founder and Co-leader of the Dutch Center for RNA Therapeutics (DCRT).

Further details

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern